Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Statins reduce the incidence of cardiovascular events in persons with type 2 diabetes mellitus. However, the benefit of statins in such patients receiving hemodialysis, who are at high risk for cardiovascular disease and death, has not been examined. METHODS: We conducted a multicenter, randomized, double-blind, prospective study of 1255 subjects with type 2 diabetes mellitus receiving maintenance hemodialysis who were randomly assigned to receive 20 mg of atorvastatin per day or matching placebo. The primary end point was a composite of death from cardiac causes, nonfatal myocardial infarction, and stroke. Secondary end points included death from all causes and all cardiac and cerebrovascular events combined. RESULTS: After four weeks of treatment, the median level of low-density lipoprotein cholesterol was reduced by 42 percent among patients receiving atorvastatin, and among those receiving placebo it was reduced by 1.3 percent. During a median follow-up period of four years, 469 patients (37 percent) reached the primary end point, of whom 226 were assigned to atorvastatin and 243 to placebo (relative risk, 0.92; 95 percent confidence interval, 0.77 to 1.10; P=0.37). Atorvastatin had no significant effect on the individual components of the primary end point, except that the relative risk of fatal stroke among those receiving the drug was 2.03 (95 percent confidence interval, 1.05 to 3.93; P=0.04). Atorvastatin reduced the rate of all cardiac events combined (relative risk, 0.82; 95 percent confidence interval, 0.68 to 0.99; P=0.03, nominally significant) but not all cerebrovascular events combined (relative risk, 1.12; 95 percent confidence interval, 0.81 to 1.55; P=0.49) or total mortality (relative risk, 0.93; 95 percent confidence interval, 0.79 to 1.08; P=0.33). CONCLUSIONS: Atorvastatin had no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infarction, and stroke in patients with diabetes receiving hemodialysis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Intensive glucose control (A1C levels <7% in T2D and <7.5% in T1D) in several clinical trials was found to reduce the risk of incident albuminuria (A2) and DKD onset.70,78,90,406–410”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [407]
In the citing paper
“Finally, in the UKPDS, wherein intensive treatment led to a mean end point A1C of 7.0%, hypoglycemia occurred in 1.8% of insulin-treated persons per year in the intensive group vs 0.7% of conventionally treated persons per year.407”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [407]
In the citing paper
“CKD is strongly associated with dyslipidemia, and CVD remains the leading cause of mortality among patients with CKD.25,26,28”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
In the citing paper
“CKD is strongly associated with dyslipidemia, and CVD remains the leading cause of mortality among patients with CKD.25,26,28”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
In the citing paper
“However, because of the gaps in data and negative study results, uncertainty exists over the benefits of applying proven CVD therapy in the general population to the CKD population, especially in patients with advanced kidney disease.”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Clinical epidemiology of cardiovascular disease in chronic renal disease
Foley, R., Parfrey, P., & Sarnak, M. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v32.pm9820470 · Cited by 3,958
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Doqi, K. (2002) · American Journal of Kidney Diseases · Cited by 1,285
The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia
Himmelfarb, J., Stenvinkel, P., Ikizler, T. A., & Hakim, R. M. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00600.x · Cited by 1,179
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- Takayama F, 1998, Cell Mol Biol, 44, 1101
Cited by
Items 701–800 of 1,004
Roberts, P. R., Stromberg, K. D., Johnson, L. C., Wiles, B. M., Mavrakanas, T. A., & Charytan, D. M. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.10.020 · Cited by 41
Vascular calcification in chronic kidney disease: the role of vitamin K
Holden, R. M., & Booth, S. L. (2007) · Nature Reviews Nephrology · doi:10.1038/ncpneph0601 · Cited by 41
Lee, C., Park, J. T., Chang, T. I., Kang, E. W., Nam, K. H., Joo, Y. S., Sung, S. A., Kim, Y. H., Chae, D., Park, S. K., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.037 · Cited by 46
Nikolić, D., Nikfar, S., Salari, P., Rizzo, M., Ray, K. K., Pencina, M. J., Mikhailidis, D. P., Toth, P. P., Nicholls, S. J., Rysz, J., et al. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.779237 · Cited by 42
An Overview of the Pathophysiology of Vascular Calcification in Chronic Kidney Disease
Stompór, T. P. (2007) · Peritoneal Dialysis International · doi:10.1177/089686080702702s37 · Cited by 40
Renal Dysfunction Potentiates Foam Cell Formation by Repressing ABCA1
Zuo, Y., Yancey, P., Castro, I., Khan, W., Motojima, M., Ichikawa, I., Fogo, A. B., Linton, M. F., Fazio, S., & Kon, V. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.188995 · Cited by 39
Yamamoto, S., Zhong, J., Yancey, P. G., Zuo, Y., Linton, M. F., Fazio, S., Yang, H., Narita, I., & Kon, V. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.055 · Cited by 41
Chang, T. I., Streja, E., Ko, G. J., Naderi, N., Rhee, C. M., Kovesdy, C. P., Kashyap, M. L., Vaziri, N. D., Kalantar‐Zadeh, K., & Moradi, H. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009096 · Cited by 43
Eldehni, M. T., Odudu, A., & McIntyre, C. W. (2019) · Hemodialysis International · doi:10.1111/hdi.12754 · Cited by 43
Arıkan, İ., Metintaş, S., Kalyoncu, C., & Yıldız, Z. (2009) · PubMed · Cited by 86
Silbernagel, G., Fauler, G., Genser, B., Drechsler, C., Krane, V., Scharnagl, H., Grammer, T. B., Baumgärtner, I., Ritz, E., Wanner, C., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.551 · Cited by 41
Self-citationRydberg, E., Birgander, M., Bondeson, A., Bondeson, L., & Willenheimer, R. B. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.12.027 · Cited by 40
Tangri, N., Shastri, S., Tighiouart, H., Beck, G. J., Cheung, A. K., Eknoyan, G., & Sarnak, M. J. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.06.024 · Cited by 40
The benefit of statins in non-cardiac vascular surgery patients
Stalenhoef, A. F. H. (2009) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2008.11.070 · Cited by 40
Prevention of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference
McCullough, P. A., Haapio, M., Mankad, S. V., Zamperetti, N., Massie, B. M., Bellomo, R., Berl, T., Anker, S. D., Anand, I. S., Aspromonte, N., et al. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq180 · Cited by 40
Chinese expert consensus on blood lipid management in patients with diabetes (2024 edition)
Xiao, Y., Yu, B., Chen, C., Wang, S., Hu, D., Wu, C., Luo, Y., Xie, L., Li, C., Peng, D., et al. (2024) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2024-0014 · Cited by 42
Ridker, P. M., Kastelein, J. J. P., Genest, J. J., & Köenig, W. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht022 · Cited by 39
Waks, J. W., Tereshchenko, L. G., & Parekh, R. S. (2016) · Journal of Electrocardiology · doi:10.1016/j.jelectrocard.2016.07.020 · Cited by 40
Is there a need to optimize glycemic control in hemodialyzed diabetic patients?
Feldt‐Rasmussen, B. (2006) · Kidney International · doi:10.1038/sj.ki.5001886 · Cited by 42
Educational Paper: Progression in chronic kidney disease and prevention strategies
Schaefer, B., & Wühl, E. (2012) · European Journal of Pediatrics · doi:10.1007/s00431-012-1814-5 · Cited by 48
Yang, X., Ronald, C. W., So, W., Ko, G. T. C., Kong, A. P. S., Lam, C. W. K., Ho, C.-S., Cockram, C. S., Wong, V. C. W., Tong, P. C. Y., et al. (2007) · Cardiovascular Diabetology · doi:10.1186/1475-2840-6-37 · Cited by 42
Drechsler, C., Krane, V., Grootendorst, D. C., Ritz, E., Winkler, K., März, W., Dekker, F. W., & Wanner, C. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp260 · Cited by 39
Self-citationBattistella, M., Jandoc, R., Ng, J. Y., McArthur, E., & Garg, A. X. (2018) · Canadian Journal of Kidney Health and Disease · doi:10.1177/2054358118760832 · Cited by 39
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.72 · Cited by 39
Phosphate and Coronary Artery Disease in Patients with Chronic Kidney Disease
Ogata, E., Sugawara, H., Yamamoto, M., & Ito, H. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22012 · Cited by 39
Tomey, M. I., & Winston, J. A. (2014) · Annals of Global Health · doi:10.1016/j.aogh.2013.12.007 · Cited by 45
Low cholesterol in dialysis patients--causal factor for mortality or an effect of confounding?
Chmielewski, M. S., Verduijn, M., Drechsler, C., Lindholm, B., Stenvinkel, P., Rutkowski, L., Boeschoten, E. W., Krediet, R. T., & Dekker, F. W. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr008 · Cited by 43
Vascular Calcification in Uremia: New-Age Concepts about an Old-Age Problem
Smith, E. R. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3353-2_13 · Cited by 40
Nanotherapeutic Shots through the Heart of Plaque
Kanthi, Y. M., de la Zerda, A., & Smith, B. R. (2020) · ACS Nano · doi:10.1021/acsnano.0c00245 · Cited by 39
Menzin, J., Lines, L. M., Weiner, D. E., Neumann, P. J., Nichols, C. I., Rodriguez, L., Agodoa, I., & Mayne, T. J. (2011) · PharmacoEconomics · doi:10.2165/11588390-000000000-00000 · Cited by 38
Reuter, S. E., Faull, R., & Evans, A. M. (2007) · Nephrology · doi:10.1111/j.1440-1797.2007.00817.x · Cited by 42
Kalantar‐Zadeh, K., Golan, E., Shohat, T., Streja, E., Norris, K. C., & Kopple, J. D. (2010) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2010.00795.x · Cited by 39
Diagnosis and Treatment of Diabetic Kidney Disease
Gosmanov, A. R., Wall, B. M., & Gosmanova, E. O. (2014) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000185 · Cited by 43
Wolf, M. S., & Thadhani, R. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2006.11.009 · Cited by 38
Risk factors for atherosclerosis in patients with chronic kidney disease: recognition and management
Balla, S., Nusair, M. B., & Alpert, M. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.12.001 · Cited by 43
Causes and consequences of inflammation on anemia management in hemodialysis patients
Chawla, L. S., & Krishnan, M. (2009) · Hemodialysis International · doi:10.1111/j.1542-4758.2009.00352.x · Cited by 48
Krane, V., Schmidt, K.-R., Gutjahr-Lengsfeld, L., Mann, J. F. E., März, W., Swoboda, F., & Wanner, C. (2016) · Kidney International · doi:10.1016/j.kint.2015.12.033 · Cited by 39
Self-citationSilva, R. T., Filho, M. M., Peixoto, G. D. L., Lima, J. J. G. D., de Siqueira, S. F., Costa, R., Gowdak, L. H. W., de Paula, F. J., Filho, R. K., & Ramires, J. A. F. (2015) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20150106 · Cited by 37
Cardiovascular Complications in Diabetic Kidney Disease
Patel, T. V., & Charytan, D. M. (2010) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2009.00704.x · Cited by 37
Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins
Scarpioni, R., Ricardi, M., Albertazzi, V., & Melfa, L. (2012) · World Journal of Nephrology · doi:10.5527/wjn.v1.i6.184 · Cited by 39
Wu, C.-C., Liou, H.-H., Su, P.-F., Chang, M., Wang, H.-H., Chen, M., & Hung, S. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr057 · Cited by 37
Ishii, H., Toriyama, T., Aoyama, T., Takahashi, H., Amano, T., Hayashi, M., Tanaka, M., Kawamura, Y., Yasuda, Y., Yuzawa, Y., et al. (2009) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.109.889915 · Cited by 37
SGLT2 inhibitors – a potential treatment for Alport syndrome
Mabillard, H. R., & Sayer, J. A. (2020) · Clinical Science · doi:10.1042/cs20191276 · Cited by 38
Kirmizis, D. A., Papagianni, A. A., Dogramatzi, F., Skoura, L., Belechri, A., Alexopoulos, E., Efstratiadis, G., & Memmos, D. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.5710 · Cited by 37
Pellicano, R., Polkinghorne, K. R., & Kerr, P. G. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.02.296 · Cited by 37
Prevention of cardiovascular disease after renal transplantation
Svensson, M. H. S., Jardine, A. G., Fellström, B., & Holdaas, H. (2012) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e3283560a3b · Cited by 37
The treatment of coronary artery disease in patients with chronic kidney disease
Edwards, N. C., Steeds, R. P., Ferro, C. J., & Townend, J. (2006) · QJM · doi:10.1093/qjmed/hcl101 · Cited by 40
Apostolov, E. O., Basnakian, A. G., Ok, E., & Shah, S. V. (2011) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2011.10.023 · Cited by 37
Lipid lowering for prevention of venous thromboembolism: a network meta-analysis
Farmakis, I. T., Christodoulou, K. C., Hobohm, L., Konstantinides, S., & Valerio, L. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae361 · Cited by 36
Tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica
Gómez‐Huelgas, R., Martínez‐Castelao, A., Artola, S., Górriz, J. L., & Torre, E. L. M. (2013) · Medicina Clínica · doi:10.1016/j.medcli.2013.10.011 · Cited by 41
Drechsler, C., Grootendorst, D. C., Pilz, S., Tomaschitz, A., Krane, V., Dekker, F. W., März, W., Ritz, E., & Wanner, C. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.05.026 · Cited by 37
Self-citationPrevalence and management of chronic kidney disease in primary care patients in the UK
Jameson, K., Jick, S. S., Hagberg, K. W., Ambegaonkar, B. M., Giles, A., & O'Donoghue, D. J. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12454 · Cited by 36
Lipoprotein Disorders and Cardiovascular Disease
Genest, J. J., & Libby, P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00047-0 · Cited by 38
Hiremath, S. S., Punnam, S. R., Brar, S. S., Goyal, S., Gardiner, J. C., Shah, A. J., & Thakur, R. K. (2010) · American Journal of Nephrology · doi:10.1159/000319461 · Cited by 36
Disorders of Lipid Metabolism and Chronic Kidney Disease in the Elderly
Choudhury, D., Tuncel, M., & Levi, M. (2009) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2009.07.006 · Cited by 40
Beta-blocker prevents sudden cardiac death in patients with hemodialysis
Matsue, Y., Suzuki, M., Nagahori, W., Ohno, M., Matsumura, A., & Hashimoto, Y. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.09.037 · Cited by 36
Atorvastatin attenuates murine anti-glomerular basement membrane glomerulonephritis
Eller, K., Eller, K., Wolf, A. M., Reinstadler, S. J., Tagwerker, A., Patsch, J. R., Mayer, G. J., & Rosenkranz, A. R. (2009) · Kidney International · doi:10.1038/ki.2009.478 · Cited by 36
Kovesdy, C. P., & Kalantar‐Zadeh, K. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.4.451 · Cited by 39
Therapies for diabetic dyslipidaemia
Bell, D. S. H., Badarin, F. J. A., & O’Keefe, J. H. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01342.x · Cited by 39
Natsuaki, M., Furukawa, Y., Morimoto, T., Sakata, R., & Kimura, T. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.07.021 · Cited by 35
Benítez, T. M., Vanderwoude, E., Han, Y., Byun, J., Cheofor, V. K., Gillespie, B. W., Saran, R., & Mathew, A. V. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac138 · Cited by 36
Cardiovascular and non‐renal complications of chronic kidney disease: Managing risk
Rossing, P. R., Hansen, T. W., & Kümler, T. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15747 · Cited by 36
Risk of Sudden Cardiac Death in Chronic Kidney Disease
Poulikakos, D. J., Banerjee, D., & Malík, M. (2013) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.12328 · Cited by 35
Euvolemia in Hemodialysis Patients: A Potentially Dangerous Goal?
Huang, S. S., Filler, G., Lindsay, R. M., & McIntyre, C. W. (2014) · Seminars in Dialysis · doi:10.1111/sdi.12317 · Cited by 38
Update on the efficacy and safety of combination ezetimibe plus statin therapy
Toth, P. P., Catapano, A. L., Tomassini, J. E., & Tershakovec, A. M. (2010) · Clinical Lipidology · doi:10.2217/clp.10.49 · Cited by 35
Feingold, K. R., & Grünfeld, C. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_14 · Cited by 50
Tran, J. N., Kao, T. C., Caglar, T., Stockl, K. M., Spertus, J. A., Lew, H. C., Solow, B. K., & Chan, P. S. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.8.901 · Cited by 35
Utilization and Costs of Cardiovascular Disease Medications in Dialysis Patients in Medicare Part D
Frankenfield, D. L., Weinhandl, E. D., Powers, C. A., Howell, B. L., Herzog, C. A., & Peter, W. L. S. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.10.047 · Cited by 35
Szummer, K. E., Lundman, P., Jacobson, S. H., Schön, S., Lindbäck, J., Stenestrand, U., Wallentin, L. C., & Jernberg, T. (2011) · Kidney International · doi:10.1038/ki.2010.524 · Cited by 36
Immune Mechanisms Involved in Cardiovascular Complications of Chronic Kidney Disease
Stinghen, A. E. M., Bucharles, S. G. E., RIELLA, M. C., & Pecoits‐Filho, R. (2010) · Blood Purification · doi:10.1159/000245636 · Cited by 35
Do structural differences in statins correlate with clinical efficacy?
Arnaboldi, L., & Corsini, A. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833b776c · Cited by 38
Khurana, M., & Silverstein, D. M. (2015) · Pediatric Nephrology · doi:10.1007/s00467-015-3075-9 · Cited by 40
Targeting vascular calcification: softening-up a hard target
Kapustin, A. N., & Shanahan, C. M. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.12.004 · Cited by 35
Instrumental variable analysis
Stel, V. S., Dekker, F. W., Zoccali, C., & Jager, K. J. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs310 · Cited by 35
Cardiovascular Disease in Patients with Chronic Kidney Disease
Weiner, D. E., & Sarnak, M. J. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0987-2.00010-8 · Cited by 38
Sudden cardiac death in CKD patients
Franczyk, B., Gluba-Brzózka, A., Wranicz, J. K., Banach, M., Olszewski, R., & Rysz, J. (2015) · International Urology and Nephrology · doi:10.1007/s11255-015-0994-0 · Cited by 38
Dyslipidemia: Management Using Optimal Lipid-Lowering Therapy
Ito, M. K. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r127 · Cited by 39
Lamprea-Montealegre, J. A., Astor, B. C., McClelland, R. L., de Boer, I. H., Burke, G. L., Sibley, C. T., O’Leary, D., Sharrett, A. R., & Szklo, M. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02090212 · Cited by 34
Exploring the Association between Macroeconomic Indicators and Dialysis Mortality
Kramer, A., Stel, V. S., Caskey, F. J., Stengel, B., Elliott, R. F., Covic, A. C., Geue, C., Cusumano, A. M., MacLeod, A. M., & Jager, K. J. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10461011 · Cited by 34
Yang, T., Lin, Y., Lin, Y., Huang, C., Chen, H.-H., & Wu, K. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.007507 · Cited by 34
Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia
Shrestha, P., van de Sluis, B., Dullaart, R. P. F., & van den Born, J. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.12.001 · Cited by 35
Vogt, L., Bangalore, S., Fayyad, R. S., Melamed, S., Hovingh, G. K., DeMicco, D. A., & Waters, D. D. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.010827 · Cited by 36
Spence, J. D., & Urquhart, B. L. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01230-6 · Cited by 35
Chmielewski, M. S., Carrero, J. J., Stenvinkel, P., & Lindholm, B. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32831ef234 · Cited by 34
Chen, H., Tsai, W., Chiu, Y., Hsu, S., Pai, M., Yang, J., & Peng, Y. (2015) · Medicine · doi:10.1097/md.0000000000000619 · Cited by 34
Determinants of Cardiovascular Risk in Haemodialysis Patients: Post hoc Analyses of the AURORA Study
Schneider, A., Jardine, A. G., Schneider, M. P., Holdaas, H., Holme, I., Fellström, B., Zannad, F. M., Schmieder, R. E., & on behalf of the AURORA Study Group (2013) · American Journal of Nephrology · doi:10.1159/000346710 · Cited by 34
Fabjan, T. H., & Hojs, R. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.08.710 · Cited by 36
Survival in end stage renal disease: calcium carbonate vs. sevelamer
Borzecki, A. M., Lee, A. F., Wang, S. W., Brenner, L., & Kazis, L. E. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00871.x · Cited by 34
Shoji, T., & Nishizawà, Y. (2006) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1744-9987.2006.00382.x · Cited by 34
Shukla, A. M., Bose, C., Karaduta, O. K., Apostolov, E. O., Kaushal, G. P., Fahmi, T., Segal, M. S., & Shah, S. V. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139226 · Cited by 36
A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
Schlackow, I., Kent, S., Herrington, W. G., Emberson, J., Haynes, R., Reith, C. A., Wanner, C., Fellström, B., Gray, A. M., Landray, M., et al. (2017) · Heart · doi:10.1136/heartjnl-2016-310970 · Cited by 38
Self-citationDo Physicians Respond to the Costs and Cost-Sensitivity of Their Patients?
Carrera, M., Goldman, D. P., Joyce, G., & Sood, N. (2018) · American Economic Journal Economic Policy · doi:10.1257/pol.20150523 · Cited by 34
Biccard, B. M. (2008) · Anaesthesia · doi:10.1111/j.1365-2044.2007.05265.x · Cited by 36
Predictors of low circulating endothelial progenitor cell numbers in haemodialysis patients
Schlieper, G., Hristov, M., Brandenburg, V. M., Krüger, T., Westenfeld, R., Mahnken, A. H., Yagmur, E., Boecker, G., Heussen, N. M., Gladziwa, U., et al. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn103 · Cited by 34
Nogueira, J. M., & Weir, M. R. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04131206 · Cited by 36
Briel, M., Nordmann, A. J., & Bucher, H. C. (2006) · Current Opinion in Internal Medicine · doi:10.1097/01.mol.0000191502.39831.ba · Cited by 34
Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism
Epstein, M. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00289-2 · Cited by 36
Bellorín-Font, E., Ambrosoni, P., Carlini, R. G., Carvalho, A. B., Correa‐Rotter, R., Cueto-Manzano, A. M., Jara, A., Jorgetti, V., Negri, A. L., Negri, A. L., et al. (2013) · PubMed · doi:10.3265/nefrologia.pre2013.feb.11945 · Cited by 33
A Clinical Review of Statins and Cancer: Helpful or Harmful?
Gonyeau, M. J., & Yuen, D. W. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.2.177 · Cited by 33
Rammos, C., Hendgen-Cotta, U. B., Sobierajski, J., Adamczyk, S., Hetzel, G. R., Kleophas, W., Dellanna, F., Kelm, M., & Rassaf, T. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.08.021 · Cited by 35
Metadata
- Authors
- Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E.
- Affiliations
- University of Würzburg (DE)
- Medical University of Graz (AT)
- University Medical Center Freiburg (DE)
- München Klinik Schwabing (DE)
- Pfizer (Germany) (DE)
- Heidelberg University (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-07-21
- Volume
- 353
- Issue
- 3
- Pages
- 238-248
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2110601215
- Cited by
- 2,614
- References
- 30
- Citations by year
- 2026: 74 · 2025: 51 · 2024: 66 · 2023: 76 · 2022: 90 · 2021: 92 · 2020: 97 · 2019: 110 · 2018: 96 · 2017: 104 · 2016: 110 · 2015: 132 · 2014: 153 · 2013: 162 · 2012: 185
- FWCI
- 135.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- atorvastatin, type 2 diabetes, hemodialysis, statins, cardiovascular events, myocardial infarction, stroke, cardiovascular mortality, LDL cholesterol, end-stage renal disease
- MeSH terms
- Atorvastatin, Aged, Cerebrovascular Disorders, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Heart Diseases, Renal Dialysis, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Prospective Studies, Pyrroles, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.